Related references
Note: Only part of the references are listed.Combined antiplatelet and anticoagulant therapy: clinical benefits and risks
J. W. Eikelboom et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The intrinsic pathway of coagulation:: a target for treating thromboembolic disease?
D. Gailani et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Factor IXa inhibitors as novel anticoagulants
Emily L. Howard et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K. Dyke et al.
CIRCULATION (2006)
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice
X Wang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Coagulation disorders of cardiopulmonary bypass: a review
D Paparella et al.
INTENSIVE CARE MEDICINE (2004)
RNA aptamers as reversible antagonists of coagulation factor IXa
CP Rusconi et al.
NATURE (2002)
A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding
CJ Refino et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Share Paper
